Latest Insider Transactions at Graphite Bio, Inc. (GRPH)
This section provides a real-time view of insider transactions for Graphite Bio, Inc. (GRPH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Graphite Bio, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Graphite Bio, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 22
2024
|
Evert B. Schimmelpennink President, CEO and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+50.0%
|
$45,000
$1.04 P/Share
|
|
May 14
2024
|
Daniel R. Chevallard Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,188
+50.0%
|
$47,820
$15.68 P/Share
|
|
May 13
2024
|
James W Mccollum Director |
BUY
Open market or private purchase
|
Indirect |
31,332
+5.63%
|
$469,980
$15.99 P/Share
|
|
Mar 21
2024
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
64,971
+8.55%
|
$974,565
$15.03 P/Share
|
|
Mar 21
2024
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
933,038
+21.94%
|
$13,995,570
$15.03 P/Share
|
|
Mar 21
2024
|
Ra Capital Management, L.P. |
BUY
Grant, award, or other acquisition
|
Indirect |
3,245,785
+50.0%
|
-
|
|
Mar 21
2024
|
James W Mccollum Director |
BUY
Grant, award, or other acquisition
|
Indirect |
494,233
+26.63%
|
$3,459,631
$7.52 P/Share
|
|
Mar 21
2024
|
James W Mccollum Director |
BUY
Grant, award, or other acquisition
|
Direct |
95,034
+50.0%
|
-
|
|
Mar 21
2024
|
Marc Odrich Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
99,599
+50.0%
|
-
|
|
Mar 21
2024
|
Versant Venture Capital Vi, L.P. |
BUY
Other acquisition or disposition
|
Indirect |
598,203
+41.53%
|
-
|
|
Apr 12
2022
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
350,000
+3.97%
|
$1,400,000
$4.08 P/Share
|
|
Apr 11
2022
|
Phil Gutry CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Direct |
5,000
+1.64%
|
$20,000
$4.01 P/Share
|
|
Apr 11
2022
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
74,464
+0.91%
|
$297,856
$4.07 P/Share
|
|
Jan 24
2022
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
23,000
+0.29%
|
$184,000
$8.7 P/Share
|
|
Jan 21
2022
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
100,000
+1.23%
|
$800,000
$8.99 P/Share
|
|
Jan 20
2022
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
43,105
+0.54%
|
$344,840
$8.92 P/Share
|
|
Jan 19
2022
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
54,565
+0.69%
|
$491,085
$9.24 P/Share
|
|
Dec 15
2021
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
22,329
+0.28%
|
$223,290
$10.19 P/Share
|
|
Nov 22
2021
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
201,685
+2.52%
|
$2,016,850
$10.15 P/Share
|
|
Oct 15
2021
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,300
+0.03%
|
$27,600
$12.49 P/Share
|
|
Oct 14
2021
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
3,100
+0.04%
|
$37,200
$12.5 P/Share
|
|
Oct 13
2021
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
45,400
+0.6%
|
$590,200
$13.22 P/Share
|
|
Oct 08
2021
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
75,000
+0.99%
|
$975,000
$13.12 P/Share
|
|
Oct 07
2021
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
9,021
+0.12%
|
$126,294
$14.94 P/Share
|
|
Oct 06
2021
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
61,475
+0.82%
|
$799,175
$13.83 P/Share
|
|
Jun 29
2021
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
500,000
+17.3%
|
$8,500,000
$17.0 P/Share
|
|
Jun 29
2021
|
Samsara Bio Capital, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
6,931,623
+36.56%
|
-
|
|
Jun 29
2021
|
Davis Jerel Director |
BUY
Open market or private purchase
|
Indirect |
180,000
+9.54%
|
$3,060,000
$17.0 P/Share
|
|
Jun 29
2021
|
Davis Jerel Director |
BUY
Conversion of derivative security
|
Indirect |
13,871,446
+47.81%
|
-
|
|
Jun 29
2021
|
Versant Venture Capital Vi, L.P. |
BUY
Open market or private purchase
|
Indirect |
180,000
+9.54%
|
$3,060,000
$17.0 P/Share
|
|
Jun 29
2021
|
Versant Venture Capital Vi, L.P. |
BUY
Conversion of derivative security
|
Indirect |
1,527,719
+50.0%
|
-
|
|
Jun 29
2021
|
Versant Venture Capital Vi, L.P. |
BUY
Conversion of derivative security
|
Direct |
12,343,727
+45.63%
|
-
|
|
Jun 29
2021
|
Smital Shah Director |
BUY
Open market or private purchase
|
Indirect |
5,882
+50.0%
|
$99,994
$17.0 P/Share
|
|
Jun 29
2021
|
Joshua Lehrer Graiwer PRESIDENT AND CEO |
BUY
Conversion of derivative security
|
Direct |
8,126
+0.69%
|
-
|
|
Jun 29
2021
|
Perry A Karsen Director |
BUY
Conversion of derivative security
|
Direct |
8,126
+4.72%
|
-
|
|
Jun 29
2021
|
Joseph Jimenez Director |
BUY
Conversion of derivative security
|
Direct |
8,126
+4.78%
|
-
|
|
Jun 29
2021
|
Phil Gutry CHIEF BUSINESS OFFICER |
BUY
Conversion of derivative security
|
Direct |
8,126
+2.69%
|
-
|
|
Jun 29
2021
|
Katherine V Stultz CHIEF OPERATING OFFICER |
BUY
Conversion of derivative security
|
Direct |
8,126
+3.63%
|
-
|
|
Apr 18
2021
|
Phil Gutry CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,383
+1.17%
|
$20,298
$6.11 P/Share
|
|
Jan 16
2021
|
Joshua Lehrer Graiwer PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
374,013
+24.48%
|
$0
$0.3 P/Share
|
|
Jan 15
2021
|
Phil Gutry CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
91,406
+24.48%
|
$0
$0.3 P/Share
|
|
Jan 14
2021
|
Joseph Jimenez Director |
BUY
Exercise of conversion of derivative security
|
Direct |
49,876
+24.49%
|
$0
$0.3 P/Share
|